Chhikara, UnitaSazawal, SudhaMishra, PravasChaubey, RekhaMahapatra, ManoranjanSaxena, Renu2016-12-302016-12-302015-11Chhikara Unita, Sazawal Sudha, Mishra Pravas, Chaubey Rekha, Mahapatra Manoranjan, Saxena Renu. C1236T polymorphism in MDR1 gene correlates with therapeutic response to imatinib mesylate in Indian patients with chronic myeloid leukaemia. National Medical Journal of India. 2015 Nov-Dec; 28(6):272-275.0970-258Xhttp://imsear.searo.who.int/handle/123456789/180759Patients with chronic myeloid leukaemia show an excellent response to treatment with imatinib. However, in some patients, the disease is resistant to imatinib. This resistance may be related to the presence of genetic variations on the drug’s pharmacokinetics and metabolism. We therefore studied three polymorphisms (C1236T, G2677T and C3435T) in the human multidrug-resistance gene (MDR1) in 86 patients with chronic myeloid leukaemia treated with imatinib. Imatinib resistance was more frequent in patients with TT genotype at locus 1236 than in those with CT/CC genotypes (p=0.003). For the other two loci (G2677T and C3435T), resistance was seen to be higher for TT genotype when compared to GG/GT and CT/CC but it was not statistically significant (p=0.13 and p=0.099). In conclusion, determination of C1236T MDR1 genotype may help to predict response to imatinib therapy in patients with chronic myeloid leukaemia. Natl Med J India 2015;28:272–5enArticle